Shopping Cart
- Remove All
Your shopping cart is currently empty
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM, suitable for studies on the treatment of type 2 diabetes mellitus.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $39 | In Stock | |
| 10 mg | $55 | In Stock | |
| 25 mg | $82 | In Stock | |
| 50 mg | $97 | In Stock | |
| 100 mg | $143 | In Stock | |
| 200 mg | $209 | In Stock | |
| 500 mg | $358 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $48 | In Stock |
| Description | Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a selective and orally active hSGLT2 inhibitor with an IC50 of 0.877 nM, suitable for studies on the treatment of type 2 diabetes mellitus. |
| Targets&IC50 | SGLT2 (human):0.877 nM |
| In vitro | Ertugliflozin L-pyroglutamic acid demonstrated >2000-fold selectivity for SGLT2 over SGLT[2]. |
| In vivo | The oral administration of Ertugliflozin L-pyroglutamic to rats acid showed concentration-dependent glucosuria[2]. |
| Synonyms | PF-04971729 L-pyroglutamic acid |
| Molecular Weight | 566 |
| Formula | C27H32ClNO10 |
| Cas No. | 1210344-83-4 |
| Smiles | OC(=O)[C@@H]1CCC(=O)N1.CCOc1ccc(Cc2cc(ccc2Cl)[C@]23OC[C@](CO)(O2)[C@@H](O)[C@H](O)[C@H]3O)cc1 |
| Relative Density. | no data available |
| Color | White |
| Appearance | Solid |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 125 mg/mL (220.85 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (7.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.